3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Nasopharyngeal Carcinoma
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharangeal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lung Neoplasms
1
Kidney Neoplasms
1
Kidney Diseases
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
CRC
1
Interventions
Nivolumab
39
pembrolizumab
30
cabozantinib
29
Specimen Handling
25
Magnetic Resonance Spectroscopy
22
Ipilimumab
20
lenvatinib
16
Axitinib
15
belzutifan
13
CTLA-4 Antigen
10
Sunitinib
9
Biopsy
9
Radiosurgery
8
atezolizumab
7
Immunoglobulin G
5
toripalimab
4
fludarabine
4
avelumab
4
aldesleukin
4
Everolimus
4
Disulfides
4
Cyclophosphamide
4
zimberelimab
3
tivozanib
3
spartalizumab
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
spartalizumab
×
90 days
×
Clear all
NCT07571551
2026-05-11
TRIPLE-PATH
Jinling Hospital, China
Phase 2
Recruiting
75 enrolled
NCT04028245
2026-04-15
SPARC-1
Columbia University
Phase EARLY_PHASE1
Completed
17 enrolled
NCT06114940
2026-03-05
PLUTO
Jinling Hospital, China
Phase 2
Terminated
17 enrolled